Expert Interview
A Second View: Understanding the data behind the newly FDA approved treatment by AstraZeneca - FASENRA® (benralizumab) ,in patients with Eosinophilic granulomatosis with polyangiitis (EGPA)
Ticker(s): AZNInstitution: Private Practice
- Rheumatologist with a speciality in autoimmune diseases.
- Currently manages 45 patients per month with Lupus Nephritis and 65 patients (total) with ANCA-Associated Vasculitis.
- Over 20 years of experience and board certified in Rheumatology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
